• Türkçe
    • English
  • Türkçe 
    • Türkçe
    • English
  • Giriş
Öğe Göster 
  •   DSpace@Amasya
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
  • WoS İndeksli Yayınlar Koleksiyonu
  • Öğe Göster
  •   DSpace@Amasya
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
  • WoS İndeksli Yayınlar Koleksiyonu
  • Öğe Göster
JavaScript is disabled for your browser. Some features of this site may not work without it.

Fixed-Dose Antiplatelet Dual Combination in Patients with Coronary Artery Disease in Turkish Population: DAPT-TR

Erişim

info:eu-repo/semantics/openAccess

Tarih

2024

Yazar

Oz, Ahmet
Toprak, Kenan
Aydin, Ertan
Sarac, Ibrahim
Dogdus, Mustafa
Opan, Selcuk
Yenercag, Mustafa

Üst veri

Tüm öğe kaydını göster

Özet

Background: Dual antiplatelet therapy (DAPT) is the treatment of choice for patients with acute and chronic coronary syndromes as it reduces mortality and prevents recurrent thrombotic complications. The assessment of both ischaemic burden and bleeding risk is crucial in deciding which DAPT to choose and how long it should be continued. Objectives: The aim of our study was to perform prospective clinical follow-up of patients receiving fixed-dose combination therapy (ASA 75 mg + clopidogrel 75 mg). Our study is a multicentric, cross-sectional, observational, cohort study. Methods: A total of 1500 patients who were started on fixed-dose combination DAPT for acute or chronic coronary syndrome were included in the study. Primary endpoints were hospitalization for any reason, hospitalization for cardiovascular cause, acute myocardial infarction, stent thrombosis, target vessel revascularization and bleeding; the secondary endpoints were death for any reason or cardiovascular cause and stroke. The significance level adopted in the statistical analysis was 5%. Results: Median age was 63 years; 78.5% of the patients were receiving DAPT treatment for acute coronary syndrome. The rates of hospitalization for cardiovascular reasons, acute myocardial infartion, stent thrombosis and target-vessel revascularization were 7.9%, 2.3%, 1.3% and 4.2%, respectively. While the rate of BARC type 1 bleeding was 3.3%, the rate of BARC type 5, 3, or 2 bleeding was 0.6%. The secondary endpoints which were death from any cause, cardiovascular death and stroke were 0.5%, 0.3% and 0.3%, respectively. Conclusion: Our study shows that fixed-dose combination therapy is effective and safe in appropriately selected patients with acute or chronic coronary syndromes.

Cilt

121

Sayı

11

Bağlantı

https://doi.org/10.36660/abc.20240202
https://hdl.handle.net/20.500.12450/5827

Koleksiyonlar

  • PubMed İndeksli Yayınlar Koleksiyonu [458]
  • Scopus İndeksli Yayınlar Koleksiyonu [1574]
  • WoS İndeksli Yayınlar Koleksiyonu [2182]



DSpace software copyright © 2002-2015  DuraSpace
İletişim | Geri Bildirim
Theme by 
@mire NV
 

 




| Yönerge | Rehber | İletişim |

DSpace@Amasya

by OpenAIRE
Gelişmiş Arama

sherpa/romeo

Göz at

Tüm DSpaceBölümler & KoleksiyonlarTarihe GöreYazara GöreBaşlığa GöreKonuya GöreTüre GöreBölüme GöreYayıncıya GöreKategoriye GöreDile GöreErişim ŞekliBu KoleksiyonTarihe GöreYazara GöreBaşlığa GöreKonuya GöreTüre GöreBölüme GöreYayıncıya GöreKategoriye GöreDile GöreErişim Şekli

Hesabım

GirişKayıt

DSpace software copyright © 2002-2015  DuraSpace
İletişim | Geri Bildirim
Theme by 
@mire NV
 

 


|| Yönerge || Rehber || Kütüphane || Amasya Üniversitesi || OAI-PMH ||

Amasya Üniversitesi Kütüphane ve Dokümantasyon Daire Başkanlığı, Amasya, Turkey
İçerikte herhangi bir hata görürseniz, lütfen bildiriniz: openaccess@amasya.edu.tr

Creative Commons License
DSpace@Amasya by Amasya University Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

DSpace@Amasya: